112804-14-5

Basic information

• Product Name: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid
• Synonyms: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid
• CAS NO: 112804-14-5
• Molecular Weight: 277.32
• Mol File: 112804-14-5.mol

Chemical Properties

• CAS DataBase Reference: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid(112804-14-5)
• EPA Substance Registry System: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid(112804-14-5)

Safety Data

• Hazardous Substances Data: 112804-14-5(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 125702-14-9 (E)-3-(methoxycarbonyl)-4-phenylbut-3-enoic acid 
• 116129-75-0 (E)-2-<(4-morpholinylcarbonyl)methyl>-trans-cinnamic acid 
• 125702-11-6 (E)-benzylidenesuccinic anhydride 
• 5653-88-3 trans-phenylitaconic acid 
• 112804-15-6 (4S)-(-)-4-benzyl-N-[2(R)-benzyl-3-(morpholinocarbonyl)propionyl]-2-oxazolidinone 
• 645-45-4 hydrocinnamic acid chloride 
• 116129-79-4 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-(2-propyl)oxazolidin-2-one 
• 116129-88-5 benzyl (2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionate 
• 116129-80-7 (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid 
• 95798-31-5 (4S)-3-(3-phenylpropionyl)-4-(2-propyl)oxazolidin-2-one 
• 126401-48-7 3-<2-(R)-benzyl-1,4-dioxo-4-morpholinobutyl>-4-(S)-isopropyl-2-oxazolidinone 
• 116129-89-6 benzyl (2R)-2-Benzyl-3-morpholinocarbonylpropionate 

Downstream Products

• 132154-79-1 (2S,4S,5S)-5-{N-[2(R)-benzyl-3-(morpholinocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2-isopropyl-N-methylhexanamide 
• 132094-06-5 (2R,4S,5S)-5-{N-[2(R)-Benzyl-3-(morpholinocarbonyl)-propionyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2,N-dimethylhexanamide 
• 132094-49-6 (3R,5S)-5-[(1S)-1-{N-[2(R)-Benzyl-3-(morpholinocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-2-cyclohexylethyl]-3-methyldihydrofuran-2(3H)-one 
• 125075-89-0 (2S,4S,5S)-5-{N-[2(R)-Benzyl-3-(morpholinocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-butylhexanamide 
• 125015-82-9 (2S,4S,5S)-5-{N-[2(R)-Benzyl-3-(morpholinocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N,N-dimethylhexanamide 
• 125075-92-5 (2S,4S,5S)-5-{N-[2(R)-Benzyl-3-(morpholinocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-ethylhexanamide 
• 114457-27-1 (R)-2-Benzyl-N-[(S)-1-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-4-morpholin-4-yl-4-oxo-butyramide 
• 150545-02-1 (R)-2-Benzyl-N-{(S)-1-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-2-[1-(2,4-dinitro-phenyl)-1H-imidazol-4-yl]-ethyl}-4-morpholin-4-yl-4-oxo-butyramide 
• 131067-26-0 (R)-2-Benzyl-N-[(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-(1-methyl-1H-imidazol-4-yl)-ethyl]-4-morpholin-4-yl-4-oxo-butyramide 
• 122224-98-0 (R)-2-Benzyl-N-{(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-thiazol-4-yl-ethyl}-4-morpholin-4-yl-4-oxo-butyramide 
• 122225-00-7 (R)-2-Benzyl-N-{(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-thiophen-2-yl-ethyl}-4-morpholin-4-yl-4-oxo-butyramide 
• 146879-15-4 (R)-N-[(S)-2-Azido-1-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-benzyl-4-morpholin-4-yl-4-oxo-butyramide 
• 140926-08-5 (2S,3R,4S)-2-<-3-(4-thiazolyl)-L-alanyl>amino>-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 122224-71-9 (R)-2-Benzyl-N-[(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-4-morpholin-4-yl-4-oxo-butyramide 

Relevant articles and documents

Modular 1,1′-Ferrocenediyl-cored P-Stereogenic Diphosphines: ′′JDayPhos′′ Series and its Use in Rhodium(I)-Catalyzed Hydrogenation

A novel ferrocene-based P-stereogenic diphospine ligand series dubbed JDayPhos was developed, which rhodium(I) complexes of some of its members exhibited excellent enantioselectivity (up to >99% ee) and high activity in asymmetric hydrogenation of β-unsubstituted or -substituted itaconates and α-methylene-γ-oxo-carboxylates. (Figure presented.).

Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S

Peptidic, non-covalent inhibitors of lysosomal cysteine protease cathepsin S (1 and 2) were investigated due to low oral bioavailability, leading to an improved series of peptidomimetic inhibitors. Utilizing phenyl succinamides as the P2 residue increased the oral exposure of this lead series of compounds, while retaining selective inhibition of the cathepsin S isoform. Concurrent investigation of the P1 and P2 subsites resulted in the discovery of several potent and selective inhibitors of cathepsin S with good pharmacokinetic properties due to the elimination of saturated aliphatic P2 residues.

Chiral 1,1'-diphosphetanylferrocenes: New ligands for asymmetric catalytic hydrogenation of itaconate derivatives

The useful combination of high catalytic activity and high enantioselectivity is provided by rhodium catalysts based on a new class of FerroTANE ligands when employed in the hydrogenation of itaconate derivatives (see scheme). Reactions performed at S/C r

PEPTIDES HAVING RENIN INHIBITORY ACTIVITY, THEIR PREPARATION AND USE

Compounds of formula (I): STR1 [in which: R 1 is heterocyclic group having 5 or 6 ring atoms, or--NR 7 R 8, where R 7 is alkyl and R 8 is optionally substituted phenyl, optionally substituted phenylalkyl or cycloalkyl; R 2 is optionally substituted phenyl

1,2,3-Trisubstituted Cyclopropanes as Conformationally Restricted Peptide Isosteres: Application to the Design and Synthesis of Novel Renin Inhibitors

The 1,2,3-trisubstituted cyclopropanes 6 and 7 are the first members of a novel class of isosteric replacements for peptide linkages that are more generally represented by the dipeptide mimics 2 and 3.These unique peptide surrogates are specifically desig

Peptidyl difluorodiol renin inhibitors

A renin inhibiting compound of the formula: wherein A is a functional group; W is (1)-C(O)-,(2)-CH(OH)-or(3)-N(R?)-wherein R? is hydrogen or loweralkyl; U is (1)-C(O)-,(2)-CH?-or(3)-N(R?)-wherein R? is hydrogen or lower alkyl, with the proviso that when W is-CH(OH)-then U is-CH?-and with the proviso that U is-C(O)-or-CH?-when W is-N(R?)-; V is (1)-CH-,(2)-C(OH)-or(3)-C(halogen)-with the proviso that v is-CH--when U is-N(R?)-; Q is-CH(R?)-or-C(=CHR1a)-wherein R? is (1) loweralkyl,(2) cycloalkylalkyl,(3) arylalkyl,(4) (heterocyclic) alkyl,(5) 1-benzyloxyethyl,(6) phenoxy,(7) thiophenoxy or(8) anilino, provided that B is-CH?-or-CH(OH)-or A is hydrogen when R? is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R? is a functional group; R? is (1) loweralkyl,(2) cycloalkylmethyl or(3) benzyl; R? is-CH(OH)-or-C(O)-; R? is-CH(OH)-or-C(O)-; and Z is (1) lower alkyl,(2) aryl,(3) arylalkyl,(4) cycloalkyl,(5) cycloalkylalkyl,(6) heterocyclic or(7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Asymmetric synthesis of 2-substituted-3-aminocarbonyl propionic acid.

An asymmetric synthetic route to 2-substituted-3-aminocarbonyl propionic acid, which is the significant component of low-molecular-weight renin inhibitors, is described. The key step of this synthesis is diastereoselective alkylation by using chiral oxazo

Renin-inhibiting peptidyl heterocycles

A renin inhibiting compound of the formula:*(formula 01)* wherein A is a substituent; W is C=O, CHOH or NR2 wherein R2 is hydrogen or loweralkyl; U is C=O, CH2 or NR2 wherein R2 is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH2 and with the proviso that U is C=O or CH2 when W is NR2; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR2; R1 is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH2 or CHOH or A is hydrogen when R1 is phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl,(alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R4 is loweralkyl, cycloalkylmethyl or benzyl; R5 is OH or NH2; and Z is a substituent. Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

Renin-inhibiting functionalized peptidyl aminodiols and - triols

A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.